
Masimo (MASI) Stock Forecast & Price Target
Masimo (MASI) Analyst Ratings
Bulls say
Masimo Corp reported strong growth in driver shipments, achieving 65,000, which surpassed expectations and marked an 8% quarter-over-quarter increase and an 11% year-over-year increase. The company also demonstrated improved profitability, with gross margins up 240 basis points and operating margins increasing by 570 basis points year-over-year, indicating operational efficiency and effective cost management. Looking ahead, Masimo reaffirmed its 2025 revenue guidance of 8-11% growth while raising its EPS guidance, reflecting confidence in continued strong performance driven by market share gains and new product launches.
Bears say
Masimo Corp's overall revenue growth has shown a decline, with the healthcare segment experiencing slower growth rates, down from 12% in the previous quarter to 9% in 4Q24, raising concerns about the company's market position in patient monitoring technologies. The bear case scenario suggests a potential further slowdown in revenue growth into mid-single digits due to decreased market share and disappointing product sales, leading to weaker-than-expected margins and earnings. Additionally, risks such as operational challenges, underperformance in new product lines, and adverse impacts from external factors like GLP-1 weight loss drugs further contribute to the negative outlook on the company’s financial stability.
This aggregate rating is based on analysts' research of Masimo and is not a guaranteed prediction by Public.com or investment advice.
Masimo (MASI) Analyst Forecast & Price Prediction
Start investing in Masimo (MASI)
Order type
Buy in
Order amount
Est. shares
0 shares